3. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Current Stock Price as of Writing: $17.50
A focused robotic urology business offers growth, alongside a widening net loss.
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is one of the purest medical robotics stocks on the list. Its AQUABEAM and HYDROS systems are used in Aquablation therapy, initially focused on treating benign prostatic hyperplasia, or an enlarged prostate. Unlike a diversified medical-device company, its results give investors a much clearer view of demand for its core robotic technology.
Second-quarter 2026 revenue rose 19% to $94.5 million. The concern is that its quarterly net loss also widened to $26.9 million, from $19.6 million a year earlier. Revenue growth is encouraging; investors still need to see whether higher procedure volumes and system use can eventually support stronger profitability.
That balance puts PROCEPT BioRobotics Corporation (NASDAQ: PRCT) at number three. It offers more concentrated robotics exposure than the large manufacturers above, but a concentrated business also leaves less room for setbacks in its principal treatment market.
